Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart

Regulatory Peptides

Volumn 165, Issue 1, 2010, Pages 63-70

  Brar, Bhawanjit K ^a,b   Helgeland, Erik ^c   Mahata, Sushil K ^a,b   Zhang, Kuixing ^b   O'Connor, Daniel T ^a,b   Helle, Karen B ^c   Jonassen, Anne K ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Catestatin; Chromogranin A; Infarction; Ischemia; Reperfusion

Indexed keywords

CATESTATIN; GLYCINE; LEUCINE; PEPTIDE DERIVATIVE; PROLINE; PROTEIN BAD; PROTEIN KINASE B; SERINE; TRANSCRIPTION FACTOR FKHR;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE FREQUENCY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; ISOLATED HEART; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEIN VARIANT; RAT; REGULATORY MECHANISM; REPERFUSION INJURY; TISSUE LEVEL; WILD TYPE;

ANIMALS; CELLS, CULTURED; CHROMOGRANIN A; HUMANS; MALE; MICE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RATS; RATS, WISTAR;

RATTUS;

EID: 78649903305     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.07.153     Document Type: Article

References (57)

1. Rodríguez-Sinovas A., Abdallah Y., Piper H.M., Garcia-Dorado D. Reperfusion injury as a therapeutic challenge in patients with acute MI. Heart Fail Rev 2007, 12:207-216.
2. Penna C., Mancardi D., Raimondo S., Geuna S., Pagliaro P. The paradigm of postconditioning to protect the heart. J Cell Mol Med 2008, 12:435-458.
3. Piper H.M., Abdallah Y., Schäfer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 2004, 61:365-371.
4. Penna C., Perrelli M.G., Raimondo S., Tullio F., Merlino A., Moro F., Geuna S., Mancardi D., Pagliaro P. Postconditioning induces an anti-apoptotic effect and preserves mitochondrial integrity in isolated rat hearts. Biochim Biophys Acta 2009, 1787:794-801.
5. Jonassen A.K., Sack M.N., Mjøs O.D., Yellon D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001, 89:1191-1198.
6. Hausenloy D.J., Yellon D.M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007, 12:217-234.
7. Ovize M., Baxter G.F., Di Lisa F., Ferdinandy P., Garcia-Dorado D., Hausenloy D.J., Heusch G., Vinten-Johansen J., Yellon D.M., Schulz R. Postconditioning and protection from reperfusion injury: where do we stand?: Position Paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res Jun 12 2010, [Epub ahead of print].
8. Omland T., Dickstein K., Syversen U. Association between plasma chromogranin A concentration and long-term mortality after MI. Am J Med 2003, 114:25-30.
9. Ceconi C., Ferrari R., Bachetti T., Opasich C., Volterrani M., Colombo B., Parrinello G., Corti A. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002, 23:967-974.
10. Jansson A.M., Røsjø H., Omland T., Karlsson T., Hartford M., Flyvbjerg A., Caidahl K. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 2009, 30:25-32.
11. Schulze P.C. Chromogranin A: friend or foe of the failing myocardium?. Eur Heart J 2007, 28:1052-1053.
12. Corti A., Ferrari R., Ceconi C. Chromogranin A and tumor necrosis factor-alpha [TNF] in chronic heart failure. Adv Exp Med Biol 2000, 482:351-359.
13. Wen G., Mahata S.K., Cadman P., Mahata M., Ghosh S., Mahapatra N.R., Rao F., Stridsberg M., Smith D.W., Mahboubi P., Schork N.J., O'Connor D.T., Hamilton B.A. Both rare and common polymorphisms contribute functional variation at CGA, a regulator of catecholamine physiology. Am J Hum Genet 2004, 74:197-207.
14. Mahata S.K., Mahata M., Wen G., Wong W.B., Mahapatra N.R., Hamilton B.A., O'Connor D.T. The catecholamine release-inhibitory "catestatin" fragment of chromogranin A: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol Pharmacol 2004, 66:1180-1191.
15. Angelone T., Quintieri A.M., Brar B.K., Limchaiyawat P.T., Tota B., Mahata S.K., Cerra M.C. The antihypertensive chromogranin A peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 2008, 149:4780-4793.
16. Takiyyuddin M.A., Brown M.R., Dinh T.Q., Cervenka J.H., Braun S.D., Parmer R.J., Kennedy B., O'Connor D.T. Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release. Auton Pharmacol 1994, 14:187-200.
17. Banks P., Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965, 97:40C-41C.
18. Blaschko H., Comline R.S., Schneider F.H., Silver M., Smith A.D. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 1967, 215:58-59.
19. Huttner W.B., Gerdes H.H., Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci 1991, 16:27-30.
20. Winkler H., Fischer-Colbrie R. The chromogranins A and B: the first 25years and future perspectives. Neuroscience 1992, 49:497-528.
21. Steiner H.J., Weiler R., Ludescher C., Schmid K.W., Winkler H. Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem 1990, 38:845-850.
22. Glattard E., Angelone T., Strub J.M., Corti A., Aunis D., Tota B., Metz-Boutigue M.H., Goumon Y. Characterization of natural vasostatin-containing peptides in rat heart. FEBS J 2006, 273:3311-3321.
23. Pieroni M., Corti A., Tota B., Curnis F., Angelone T., Colombo B., Cerra M.C., Bellocci F., Crea F., Maseri A. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007, 28:1117-1127.
24. Tatemoto K., Efendi S., Mutt V., Makk G., Feistner G.J., Barchas J.D. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986, 324:476-478.
25. Aardal S., Helle K.B., Elsayed S., Reed R.K., Serck-Hanssen G. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 1993, 5:405-412.
26. Mahata S.K., O'Connor D.T., Mahata M., Yoo S.H., Taupenot L., Wu H., Gill B.M., Parmer R.J. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997, 100:1623-1633.
27. Mazza R., Gattuso A., Mannarino C., Brar B.K., Barbieri S.F., Tota B., Mahata S.K. Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am J Physiol Heart Circ Physiol 2008, 295:H113-H122.
28. Bell R.M., Yellon D.M. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 2003, 35:185-193.
29. Mullonkal C.J., Toledo-Pereyra L.H. Akt in ischemia and reperfusion. J Invest Surg 2007, 20:195-203.
30. Huang H., Tindall D.J. FOXO factors: a matter of life and death. Future Oncol 2006, 2:83-89.
31. Juhasz B., Thirunavukkarasu M., Pant R., Zhan L., Penumathsa S.V., Secor E.R., Srivastava S., Raychaudhuri U., Menon V.P., Otani H., Thrall R.S., Maulik N. Bromelain induces cardioprotection against ischemia-reperfusion injury through Akt/FOXO pathway in rat myocardium. Am J Physiol Heart Circ Physiol 2008, 294:H1365-H1370.
32. Alcendor R.R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., Tian B., Wagner T., Vatner S.F., Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007, 100:1512-1521.
33. Li X.L., Man K., Ng K.T., Sun C.K., Lo C.M., Fan S.T. The influence of phosphatidylinositol 3-kinase/Akt pathway on the ischemic injury during rat liver graft preservation. Am J Transplant 2005, 5:1264-1275.
34. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281(5381):1322-1326.
35. Zha J., Harada H., Osipov K., Jockel J., Waksman G., Korsmeyer S.J. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem 1997, 272:24101-24104.
36. Biswas N., Vaingankar S.M., Mahata M., Das M., Gayen J.R., Taupenot L., Torpey J.W., O'Connor D.T., Mahata S.K. Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin. Endocrinology 2008, 149:749-757.
37. Scamuffa N., Calvo F., Chrétien M., Seidah N.G., Khatib A.M. Proprotein convertases: lessons from knockouts. FASEB J 2006, 20:1954-1963.
38. Biswas N., Rodriguez-Flores J.L., Courel M., Gayen J.R., Vaingankar S.M., Mahata M., Torpey J.W., Taupenot L., O'Connor D.T., Mahata S.K. Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides. Endocrinology 2009, 150:3547-3557.
39. Burley D.S., Baxter G.F. B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol 2007, 102:529-541.
40. Stensløkken K.O., Rutkovskiy A., Kaljusto M.L., Hafstad A.D., Larsen T.S., Vaage J. Inadvertent phosphorylation of survival kinases in isolated perfused hearts: a word of caution. Basic Res Cardiol 2009, 104:412-423.
41. Simpson P., Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res 1982, 50:101-116.
42. Brar B.K., Jonassen A.K., Egorina E.M., Chen A., Negro A., Perrin M.H., Mjøs O.D., Latchman D.S., Lee K.F., Vale W. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 2004, 145:24-35.
43. Mahata S.K., Mahata M., Wakade A.R., O'Connor D.T. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. Mol Endocrinol 2000, 14:1525-1535.
44. Mahata S.K., Mahata M., Parmer R.J., O'Connor D.T. Desensitization of catecholamine release: the novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem 1999, 274:2920-2928.
45. Rao F., Wen G., Gayen J.R., Das M., Vaingankar S.M., Rana B.K., Mahata M., Kennedy B.P., Salem R.M., Stridsberg M., Abel K., Smith D.W., Eskin E., Schork N.J., Hamilton B.A., Ziegler M.G., Mahata S.K., O'Connor D.T. Catecholamine release-inhibitory peptide catestatin (chromogranin A352-372): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 2007, 115:2271-2281.
46. Vaingankar S.M., Li Y., Corti A., Biswas N., Gayen J., O'Connor D.T., Mahata S.K. Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout. Physiol Genomics 2010, 41:91-101.
47. Negro A., Brar B.K., Gu Y., Peterson K.L., Vale W., Lee K.F. erbB2 is required for G protein-coupled receptor signaling in the heart. Proc Natl Acad Sci USA 2006, 103:15889-15893.
48. Heidrich F.M., Zhang K., Estrada M., Huang Y., Giordano F.J., Ehrlich B.E. Chromogranin B regulates calcium signaling, nuclear factor kappaB activity and brain natriuretic peptide production in cardiomyocytes. Circ Res 2008, 102:1230-1238.
49. Barrabés J.A., Garcia-Dorado D., Ruiz-Meana M., Piper H.M., Solares J., González M.A., Oliveras J., Herrejón M.P., Soler Soler J. Myocardial segment shrinkage during coronary reperfusion in situ. Relation to hypercontracture and myocardial necrosis. Pfluegers Arch 1996, 431:519-526.
50. Griffiths E.J., Halestrap A.P. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995, 307:93-98.
51. Penna C., Rastaldo R., Mancardi D., Raimondo S., Cappello S., Gattullo D., Losano G., Pagliaro P. Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. Basic Res Cardiol 2006, 101:180-189.
52. Fang N.X., Yao Y.T., Shi C.X., Li L.H. Attenuation of ischemia-reperfusion injury by sevoflurane postconditioning involves protein kinase B and glycogen synthase kinase 3 beta activation in isolated rat hearts. Mol Biol Rep Mar 10 2010, [Epub ahead of print].
53. Mahapatra N.R. Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. Cardiovasc Res 2008, 80:330-338.
54. Cappello S., Angelone T., Tota B., Pagliaro P., Penna C., Rastaldo R., Corti A., Losano G., Cerra M.C. Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am J Physiol Heart Circ Physiol 2007, 293:H719-H727.
55. Helle K.B. The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc Res 2010, 85:9-16.
56. Briolat J., Wu S.D., Mahata S.K., Gonthier B., Bagnard D., Chasserot-Golaz S., Helle K.B., Aunis D., Metz-Boutigue M.H. New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell Mol Life Sci 2005, 62:377-385.
57. Jean-François F., Khemtémourian L., Odaert B., Castano S., Grélard A., Manigand C., Bathany K., Metz-Boutigue M.H., Dufourc E.J. Variability in secondary structure of the antimicrobial peptide Cateslytin in powder, solution, DPC micelles and at the air-water interface. Eur Biophys J 2007, 36:1019-1027.